152 related articles for article (PubMed ID: 32789809)
21. Confirmation of Biosimilarity in a Pharmacokinetic/Pharmacodynamic Study in Healthy Volunteers for an Analytically Highly Similar Pegfilgrastim.
Desai K; Catalano T; Rai G; Misra P; Shah N
Clin Pharmacol Drug Dev; 2016 Sep; 5(5):354-63. PubMed ID: 27138868
[TBL] [Abstract][Full Text] [Related]
22. Comparative effectiveness of pegfilgrastim biosimilars vs originator for prevention of febrile neutropenia: A retrospective cohort study.
Wang CY; Vouri SM; Park H; Heldermon CD; Brown JD
J Manag Care Spec Pharm; 2023 Feb; 29(2):119-127. PubMed ID: 36705287
[No Abstract] [Full Text] [Related]
23. Conversion to supportive care with biosimilar pegfilgrastim-cbqv enables budget-neutral expanded access to R-CHOP treatment in non-Hodgkin lymphoma.
McBride A; MacDonald K; Abraham I
Leuk Res; 2021 Jul; 106():106591. PubMed ID: 33957339
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy.
Kahan Z; Grecea D; Smakal M; Tjulandin S; Bondarenko I; Perjesi L; Illes A; Horvat-Karajz K; Aradi I
BMC Cancer; 2019 Feb; 19(1):122. PubMed ID: 30727980
[TBL] [Abstract][Full Text] [Related]
25. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
Brito M; Esteves S; André R; Isidoro M; Moreira A
Support Care Cancer; 2016 Feb; 24(2):597-603. PubMed ID: 26111956
[TBL] [Abstract][Full Text] [Related]
26. Clinical confirmation to demonstrate similarity for a biosimilar pegfilgrastim: a 3-way randomized equivalence study for a proposed biosimilar pegfilgrastim versus US-licensed and EU-approved reference products in breast cancer patients receiving myelosuppressive chemotherapy.
Desai K; Misra P; Kher S; Shah N
Exp Hematol Oncol; 2018; 7():22. PubMed ID: 30202638
[TBL] [Abstract][Full Text] [Related]
27. A glycosylated recombinant human granulocyte colony stimulating factor produced in a novel protein production system (AVI-014) in healthy subjects: a first-in human, single dose, controlled study.
Varki R; Pequignot E; Leavitt MC; Ferber A; Kraft WK
BMC Clin Pharmacol; 2009 Jan; 9():2. PubMed ID: 19175929
[TBL] [Abstract][Full Text] [Related]
28. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.
Green MD; Koelbl H; Baselga J; Galid A; Guillem V; Gascon P; Siena S; Lalisang RI; Samonigg H; Clemens MR; Zani V; Liang BC; Renwick J; Piccart MJ;
Ann Oncol; 2003 Jan; 14(1):29-35. PubMed ID: 12488289
[TBL] [Abstract][Full Text] [Related]
29. A Phase I study to determine safety, pharmacokinetics, and pharmacodynamics of ANF-RHO™, a novel PEGylated granulocyte colony-stimulating factor, in healthy volunteers.
Misra H; Berryman J; Jubin R; Abuchowski A
Invest New Drugs; 2018 Feb; 36(1):75-84. PubMed ID: 28752433
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy.
Crawford J
Pharmacotherapy; 2003 Aug; 23(8 Pt 2):15S-19S. PubMed ID: 12921218
[TBL] [Abstract][Full Text] [Related]
31. Patient out-of-pocket and payer costs for pegfilgrastim originator vs biosimilars as primary prophylaxis of febrile neutropenia in the first cycle among a commercially insured population.
Wang CY; Park H; Heldermon CD; Vouri SM; Brown JD
J Manag Care Spec Pharm; 2022 Jul; 28(7):795-802. PubMed ID: 35737859
[No Abstract] [Full Text] [Related]
32. Pegfilgrastim-jmdb/MYL-1401H: A Pegfilgrastim Biosimilar.
Hoy SM
BioDrugs; 2019 Feb; 33(1):117-120. PubMed ID: 30701419
[TBL] [Abstract][Full Text] [Related]
33. Comparing granulocyte colony-stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients.
Botteri E; Krendyukov A; Curigliano G
Eur J Cancer; 2018 Jan; 89():49-55. PubMed ID: 29227817
[TBL] [Abstract][Full Text] [Related]
34. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
Perrier L; Lefranc A; Pérol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C
Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861
[TBL] [Abstract][Full Text] [Related]
35. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
Holmes FA; O'Shaughnessy JA; Vukelja S; Jones SE; Shogan J; Savin M; Glaspy J; Moore M; Meza L; Wiznitzer I; Neumann TA; Hill LR; Liang BC
J Clin Oncol; 2002 Feb; 20(3):727-31. PubMed ID: 11821454
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer receiving chemotherapy.
Volovat C; Gladkov OA; Bondarenko IM; Barash S; Buchner A; Bias P; Adar L; Avisar N
Clin Breast Cancer; 2014 Apr; 14(2):101-8. PubMed ID: 24485296
[TBL] [Abstract][Full Text] [Related]
37. Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia.
Waller CF; Ranganna GM; Pennella EJ; Blakeley C; Bronchud MH; Mattano LA; Berzoy O; Voitko N; Shparyk Y; Lytvyn I; Rusyn A; Popov V; Láng I; Beckmann K; Sharma R; Baczkowski M; Kothekar M; Barve A
Ann Hematol; 2019 May; 98(5):1217-1224. PubMed ID: 30824956
[TBL] [Abstract][Full Text] [Related]
38. Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients.
Molineux G
Anticancer Drugs; 2003 Apr; 14(4):259-64. PubMed ID: 12679729
[TBL] [Abstract][Full Text] [Related]
39. LA-EP2006: A Pegfilgrastim Biosimilar.
Hoy SM
BioDrugs; 2019 Apr; 33(2):229-232. PubMed ID: 30887256
[TBL] [Abstract][Full Text] [Related]
40. Pharmacodynamics, safety, and immunogenicity of Pelmeg
Wessels H; Lehnick D; Höfler J; Jankowsky R; Chamberlain P; Roth K
Pharmacol Res Perspect; 2019 Oct; 7(5):e00507. PubMed ID: 31417681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
